Dapansutrile

DRUG8 trials

Sponsors

Kantonsspital Baden AG, Olatec Therapeutics LLC, April Salama, M.D., University of Virginia, Marc Donath

Conditions

Acute Gout FlareArthritisDiabetes Mellitus, Type 2GoutGout AttackGout FlareGouty ArthritisJoint Pain

Early Phase 1

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Not yet recruitingNCT05880355

University of VirginiaMyocardial Infarction

Start: 2026-04-01End: 2029-01-30Target: 60Updated: 2025-06-04

Phase 1

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Active, not recruitingNCT04971499

April Salama, M.D.Melanoma

Start: 2022-09-06End: 2027-04-30Updated: 2026-02-20

Phase 2

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

TerminatedNCT03595371

Olatec Therapeutics LLCSchnitzler Syndrome

Start: 2018-05-15End: 2018-05-29Updated: 2024-02-02

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

RecruitingNCT05658575

Olatec Therapeutics LLCAcute Gout Flare, Arthritis, Gout +4

Start: 2023-01-06End: 2027-01-31Target: 300Updated: 2026-03-11

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

RecruitingNCT06047262

Marc DonathDiabetes Mellitus, Type 2

Start: 2024-07-09End: 2028-07-31Target: 300Updated: 2026-02-25

A Multi-Center Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects with an Acute Gout Flare

RecruitingCTIS2024-518844-20-00

Olatec Therapeutics LLCTreatment of Acute Gout Flare

Start: 2023-10-03Target: 98Updated: 2025-12-16

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects with Type 2 Diabetes Mellitus Dapan-Dia Study

RecruitingCTIS2024-511828-14-00

Kantonsspital Baden AGType II diabetes melittus (10067585)

Start: 2025-05-13Target: 230Updated: 2025-07-09

A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease

RecruitingNCT07157735

Cambridge University Hospitals NHS Foundation TrustParkinson Disease

Start: 2026-02-02End: 2028-02-01Target: 36Updated: 2026-02-27

Related Papers

Abstract 4115645: NLRP3 Inflammasome Inhibition With Dapansutrile in Type 2 Diabetes and Elevated Systemic Inflammation: Rationale and Design of the DAPAN-DIA study

Circulation2024-11-12